Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] DPP-4 inhibitors and risk of heart failure EXAMINEd

In The Lancet, Faiez Zannad and colleagues1 report on heart failure and mortality outcomes in patients taking alogliptin in a post-hoc analysis of the EXAMINE trial. This report has been eagerly awaited because, in October, 2013, two randomised, placebo-controlled trials, SAVOR TIMI 532 and EXAMINE,3 which assessed blood-glucose lowering with DPP-4 inhibitors, one with saxagliptin and one with alogliptin, reported cardiovascular outcomes. An unexpected 27% increase in hospital admissions for heart failure was shown in SAVOR TIMI 53.

email